Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

doi:10.1200/JCO.2005.03.1021

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2006

Byrd John C, Gribben John G, Peterson Bercedis L, Grever Michael R, Lozanski Gerard, Lucas David M, Lampson Ben, Larson Richard A, Caligiuri Michael A, Heerema Nyla A

Abstract excerpt

PURPOSE: Several new prognostic factors predicting rapid disease progression in chronic lymphocytic leukemia (CLL) have been identified, including unmutated Ig V(H) mutational status, del(11)(q23), del(17)(p13.1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy. METHODS: We examined the impact of these new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Genes, Immunoglobulin Heavy Chain

Share to Immunologic Factors

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Randomized Controlled Trials as Topic

Share to Rituximab

Share to Vidarabine

Source

Open in PubMed

Identifiers

PMID: 16344317
DOI: 10.1200/JCO.2005.03.1021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.PMID 16344317Read ↗

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.Semantic proximity Read ↗

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.Semantic proximity Read ↗

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Semantic proximity Read ↗

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaSemantic proximity Read ↗

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.Semantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.Semantic proximity Read ↗

Understanding and managing ultra high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).Semantic proximity Read ↗

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.Semantic proximity Read ↗

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.